M&A Deal Summary |
|
|---|---|
| Date | 2019-02-14 |
| Target | CBD Naturals |
| Sector | Consumer Products |
| Buyer(s) | Isodiol |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Sector | Consumer Products |
| Revenue | 22M CAD (2019) |
Isodiol is a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products engages in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products. Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and aggressively continuing international expansion into Latin America, Asia and Europe. Isodiol is based in Vancouver, British Columbia.
| DEAL STATS | # |
|---|---|
| Overall | 9 of 9 |
| Sector: Consumer Products M&A | 4 of 4 |
| Type: Add-on Acquisition M&A Deals | 8 of 8 |
| State: California M&A | 3 of 3 |
| Country: United States M&A | 5 of 5 |
| Year: 2019 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-04-17 |
Hankang Biotech Co. - Three Pivotal Processing Patents
China Hankang (Yunnan) Biotech Co., Ltd. - Three Pivotal Processing Patents includes three patents for processing and extracting CBD. |
Buy | $500K |
